RESEARCH MEETING
May ~~20~~ 19, 1992

In preparation for our meeting on May ~~20~~ 19, 1992, it will be helpful to have the information regarding Philip Morris primary research that I have been able to gather over the past several months. If anything is omitted, please let me know as soon as possible. I would not like anything to show up later which will affect our funding decisions for 1993.

Our purpose, on May ~~20~~ 19, will be to discuss the merits of all currently funded research and research proposals in order to assist in determining what research we should fund in 1993. (1) Foremost in our consideration should be the scientific quality of the research. (2) Second, will the research move us toward an answer to the question of what, if any, role cigarette smoking may play in certain diseases? (3) Third, will the research help provide answers to the questions of what factors play a role in some of the diseases associated with cigarette smoking? Finally, what other criteria should play a role in our recommendations? For example, is it important to support research in certain countries, because we need to have a "research presence" in certain markets?

I will start by listing the research we are currently sponsoring (1992), the current funding amounts, and the Philip Morris organization currently responsible for the funding. I will also include, to the extent I am aware, future funding obligations. This will be followed by research proposals for future funding.

(1) Res. for strategic reasons (various, themes) → different Budget.
Money for research and not for research! Within ↔ Research Budget A/S ?
Basic / Applied research.
(2) Acknowledgement obligation!! Philip Morris, Wolff, NIMA should appear.
(3) Res. fund, contribution by all countries & pool for litigation

2028392525

2028392525

Source: https://www.industrydocuments.ucsf.edu/docs/nrpb0003

I. **Primary Issue Grants formerly with FTR-S&T, now with Philip Morris-USA (Jim Charles).**

CATEGORY	Researcher	Title and Comments	1992 Funding (CHF)	1993
A PROPOSED B ASIC	Caboche	Neurophysiology (thesis); this is only for 1992; University of Paris	20,400	—
B	Tassin	Neuroreceptors - nicotine receptors in the brain and tobacco's effect on increasing learning and concentration; College of France Last yr - 93	89,100	89.100 Cont.
A	Dusser	Airway enzymes - what happens to enzymes after exposure to smoke; Faculty of Medicine-Paris	57,300	Cont.
A	Molimard	Smoking behavior; Faculty of Medicine-Paris approved AFNOR	63,600	
B	Micheletti	Parkinson's disease - study in rats; Strasbourg UNIV, FAC. MED.	57,300	
B	Hirt	Papilloma virus - possible involvement of viruses in some cancers; Swiss Institute for Experimental Cancer Research Only CH - in care → ASFC ←	95,000	ASFC Cont.
A	Syrjaenen	Papilloma virus - looking at lung cancer, laryngeal cancer and HPV; University of Kuopio, Finland	→ CHF 162K 131,800	
A	Schneider	Biometrics - risk assessment; using computer models to show competitive risks; University of Hanover	finding cut because of decision on Alco. (BAT, PM, RJR → book 3) CHF +32,000 98,700	—

2028392526

2028392526

Source: https://www.industrydocuments.ucsf.edu/docs/nrpb0003

CHF 1993

Symann	Oncology - post-doctorate fellowship; cell transformation through solid tumors; Brussels	55,000
Vincze	DNA adducts - adduct levels are not related to cancer; Institute of Public Health, Budapest	60,000

All of the above are one year commitments.

I understand that there is funding through Covington & Burling, but that it is considered ETS research.

Kings College (Prof. Gorrod)	Tobacco Alkaloids ETS ? nicotine metabolism	37,900
Kings College (Prof. Gorrod)	Nicotine Conjugates & Enzymatic	55,600
Weetman (IAI)	Decision Making MAC'o	50,000
Nilsen (Trondheim U.)	Nicotine Measurements INBIFO, Cochman influence	$252,400

II. Netherlands (Stichting).

Researcher	Title and Comments	1992 Funding (Dfl)
Anthonie von Leeuwenhoekhuis	Basic cancer research; The Dutch Cancer Institute	27,500
CIVO/TNO Institute	Research re influence of cigarette smoke on bronchial tubes and influence of Vitamin A	55,000

2028392527

2028392527

Source: https://www.industrydocuments.ucsf.edu/docs/nrpb0003

Snow	Genotoxic factors regarding the arising of head and neck cancer; Amsterdam Free University ENT Clinic	66,000
Van Bekkum	Radiobiologic research; Radiobiologic Institute	-
	Total	148,500
	20%	$16,500

III. **Switzerland (AFSC).**

Researcher	Title and Comments	1992 Budget (CHF)
Bättig	Behavior and benefits of smoking;	100,000
Brunner	Hypertension; ? Letter proposal!	100,000
Cerutti	Molecular biology; + Sci Adv → CHF 100,000 → AICA's budget	100,000
Haab	Respiratory physiology;	100,000
	Total	400,000
	PM Total	200,000

Hirt, Davis data! mailed

IV. **Belgium (Fetetab).**

Researcher	Title and Comments	1992 Budget (CHF)
Malherbe	Benefits of smoking - behavior study; (paid for by PM-Belgium Marketing);	9,000

2028392528

2028392528

Source: https://www.industrydocuments.ucsf.edu/docs/nrpb0003

V. **Australia (ATRF).**

Grants	1992 Funding (Aust. $)
P.G. Board	49,733
D.G. Byrne	76,690
J.E. Kellow	44,235
Continuing Grants (previous years)	147,000
Scholarships	
M.C. Bates	17,800
G. Grigoriadis	14,180
Continuing Scholarships (previous years)	14,180
Program Grants	187,000
Total	550,818
PM Total 35%	192,786

Attached, as Exhibit A, is a memo to me from Phil Francis, dated February 14, 1992, listing some of the research projects currently being funded by the ATRF.

VI. **Inbifo.**

A. Yearly budget: approximately $14,000,000
PM-USA share $11,681,000
FTR → R+D/AMA approximately $2,319,000
from S+T
CRC yearly budget: $5,100,000 (already included in the approximately $14,000,000).

B. Breakdown of Activities: see attached Exhibit B.

2028392529

2028392529

Source: https://www.industrydocuments.ucsf.edu/docs/nrpb0003

C. **Research Goals:**

23.2%	1.	Critically evaluate credible claims regarding the biological activity of mainstream smoke. (oncogenes, TSNA, mutants)
24.8%	2.	Identify the differences between the biological activity of fresh sidestream and ETS-like smoke.
11.9%	3.	Identify and investigate pertinent single smoke components and smoke fractions, in order to decrease the biological activity of smoke.
7.1%	4.	Investigate the suitability of smoke components (nicotine) for the biomonitoring of smoke uptake.
10.6%	5.	Evaluate the impact of product modifications on biological activity, and recommend desirable changes.
11.1%	6.	Generate and investigate alternative aerosols.
.3%	7.	Ensure product quality by monitoring residues and contaminants.
10.8%	8.	Enhance the consulting expertise in order to provide reliable information and technical support.

VII. **Philip Morris-USA.**

A. **Consultants:**

1.	Abood	- Nicotine Pharmacology; - $85,000/year research grant; - $5,000/year consultancy.
2.	Guzelian	- Adverse Effects of Toxic Substances in the Environment; - $100,000/year to October 1993; - $1,000/day consultancy.

22% Product related
11% Applied Research
67% Banc

Quantification of "other constituents" in TSmoke
— ingredients
Irritation as starter of pleurocarcinogenesis

2028392530

2028392530

Source: https://www.industrydocuments.ucsf.edu/docs/nrpb0003

3. Rylander
- -Role of Airborne Glucan and Endotoxin in Indoor Air Quality -- CIAR Project.
- Lung Cancer: Role of Factors other than Smoking -- Emphasis on Diet. (Case-control epidemiological study funded by Swedish Medical Board. Also collaboration with Linda Koo, Hong Kong).
- $60,000/year unrestricted research grant;
- $90,000/year consultancy.

B. Case Western University: Drs. Friedland and Whitehouse. The Effects of Cigarette Smoking on the Development of Alzheimer's Disease: Epidemiological, Clinical and Neurobiological Studies.

Funding Commitments:

1992	- $1,240,000
1993	- 2,100,000
1994	- 700,000

C. Meyer Friedman Institute, San Francisco. Epidemiological study of 3,000 persons with Type A behavior. One-half will receive five years of Type A counseling designed to modify their behavior, while the other half will receive no counseling. The subjects will be monitored for ten years, to monitor the development of heart disease and cancer. The issue to be addressed is: what, if any, role does Type A behavior play in the development of heart disease and cancer in previously healthy individuals.

Funding Commitment:

November 1, 1992	- $ 697,000

Funding Request:

November 1993-November 1998	- $6,479,577

2028392531

2028392531

Source: https://www.industrydocuments.ucsf.edu/docs/nrpb0003

VIII. **Verband (VdC).**

I am enclosing several documents, provided by Walter Fink, all with the designation, Exhibit C. They are as follows:

A. The estimated maximum expenditures, in DM, for 1991. Enclosure 1. Actual expenditures come to approximately 5,800,000 DM. Attached, as Enclosure 2, are brief descriptions of some of the projects under items 2 and 3 of the budget - "Research projects laboratory Munich" and "Scientific research for the industry."

B. The estimated maximum expenditures, in DM, for 1992. Enclosure 3. Once again, attached are brief descriptions of some of the projects under items 2 and 3 of the budget. Enclosure 4.

C. Identified as Enclosure 5 are specific projects for 1992, with funding amounts. All of these should be reflected in the 1992 budget.

D. Identified as Research Council, Enclosure 6 explains the research, listed by researcher, under item 6 of the 1992 budget. The * beside the name means that the project is listed under item 6.

The figures are for the total budget, of which Philip Morris's share is about 34%. As of May 7, 1992, the exchange rate was $1 = 1.6032 DM.

2028392532

2028392532

Source: https://www.industrydocuments.ucsf.edu/docs/nrpb0003

To the best of my knowledge, the Wynder proposal remains unfunded. You may recall that the VdC has budgeted 250,000 DM each year for two years, and would like Philip Morris, R.J. Reynolds and British American Tobacco to come up with a total of 60,000 DM each year, for the next two years. You may also recall that this is an epidemiological study of lung cancer incidence in Japan and the United States.

IX. Philip Morris Prize Awards.

I understand that there are three Philip Morris Prize Awards (France, Italy and Germany) of 100,000 CHF each given every year. The awards are administered through Philip Morris Corporate Affairs - EEC.

X. Other Consultants.

There are a number of other consultants, most of whom appear to work in the ETS area. I list them, along with some information, in case we wish to discuss their work further, if it pertains to the primary issue.

(1) Hans Altmann (molecular biologist)
H. Gaisch — Austria

(2) Digby Anderson
P. Martin — London

2028392533

2028392533

Source: https://www.industrydocuments.ucsf.edu/docs/nrpb0003

(3)	Peter Atteslander Shook, Hardy & Bacon	Switzerland
(4)	Karl Baettig (nicotine)	Switzerland
(5)	D. Bienfait Covington & Burling	France
(6)	C. Bieva Shook, Hardy & Bacon	Belgium
(7)	Jean Boddewgn Covington & Burling	Belgium
(8)	A. Cerioli (science communication ETS) Covington & Burling	Italy
(9)	G. Crepat (Member of Aria) Covington & Burling	France
(10)	J. Descotes (ETS) Covington & Burling	U.S.A.
(11)	S. Dinardi Covington & Burling	U.S.A.
(12)	J. Faccini Covington & Burling	France
(13)	A. Fave Covington & Burling	France
(14)	J.E.R. Frijters (part of Arise Group)	Netherlands
(15)	R. Fritsch Covington & Burling	France
(16)	G. Gori Covington & Burling	U.S.A.
(17)	J. Gorrod P. Martin	U.K.

2028392534

2028392534

Source: https://www.industrydocuments.ucsf.edu/docs/nrpb0003

(18)	P. Guisnet Covington & Burling	France
(19)	P. Hellstroem Covington & Burling	Sweden
(20)	M. P. Iurato Covington & Burling	Italy
(21)	K.S. Larsson Covington & Burling	Sweden
(22)	P. Lee Covington & Burling	U.K.
(23)	G. B. Leslie Covington & Burling	U.K.
(24)	F. Lunau Covington & Burling	U.K.
(25)	T. Malmfors Covington & Burling	Sweden
(26)	L. Manzo Covington & Burling	Italy
(27)	B. Martin Covington & Burling	U.K.
(28)	B. Mikaelsson Covington & Burling	France
(29)	A. Navarro Covington & Burling	France
(30)	G. Neurath Covington & Burling	Germany
(31)	O. Nilsen Covington & Burling	Norway
(32)	R. Perry Covington & Burling	U.K.

2028392535

2028392535

Source: https://www.industrydocuments.ucsf.edu/docs/nrpb0003

(33)	A. Poma Shook, Hardy & Bacon	Italy
(34)	M. Reasor Covington & Burling	U.S.A.
(35)	A. Rico Covington & Burling	France
(36)	G. Robertson Covington & Burling	U.S.A.
(37)	F.J.C. Roe Covington & Burling	U.K.
(38)	B. Schneider	Germany
(39)	S. Schwartz Covington & Burling	U.S.A.
(40)	A. Sherlock	U.K.
(41)	P. Skrabanek Covington & Burling	Ireland
(42)	J. P. Tassin (nicotine)	France
(43)	D. Thorburn Covington & Burling	Sweden
(44)	G. Tymen Covington & Burling	France
(45)	A. Viala Covington & Burling	France
(46)	T. Voss	Denmark
(47)	J. Wahren (nicotine and Arise)	Sweden
(48)	D. M. Warburton (nicotine)	U.K.
(49)	D. F. Weetman Covington & Burling	U.K.

2028392536

2028392536

Source: https://www.industrydocuments.ucsf.edu/docs/nrpb0003

(50) L. Werkoe
Covington & Burling Sweden

(50) A. Westlin
Covington & Burling Sweden

XI. **Research Applications.**

A. Meyer Friedman Institute: see VII. C.

B. Duke University - Dr. Red Williams. See Exhibit D. Research into the effects of stress and increased cholesterol levels on the development and spread of tumors. This is animal and cell research, as contrasted with the epidemiological research of Dr. Friedman. Duke is requesting:

1992 - $380,000

1993 - 380,000.

C. Medical College of Virginia - Linden Eves. Jim Charles or Richard Carchman will explain. (NO) MONO/DIZYGOTIC TWINS TO EXPAND FROM VA → NC | BETTER FEDERAL NATURE VS NURTURE

D. Johns Hopkins University School of Medicine: see attached Exhibit E. (NO)

E. Peter Lee. Statistical analysis of accuracy of disease diagnosis. Peter Martin will explain. ~~£5,000~~ ≠ 23000 See Exhibit F. → $60.00

F. D. Warburton. For partial sponsorship of a conference on "Quality of Life Issues," which will have multi-industry support. The conference is planned for late 1992. Peter Martin will explain. £20,000. joint sponsorship with BAT, RJT. Europe? Possible involvement of Kraft, Miller, Richard?

2028392537

2028392537

Source: https://www.industrydocuments.ucsf.edu/docs/nrpb0003

G. Anthony Papconstantinou - Greece. Study of the correlation between the presence of Glutathione S-Transferase μ and the development and histological type of lung cancer in smokers. See attached Exhibit G. $60,500+. See Exhibit G.

H. Hans Altmann. See Exhibit H.

I hope that our discussions will lead to some consensus on what research Philip Morris should fund in 1993 and, if necessary, beyond.

2028392538

Source: https://www.industrydocuments.ucsf.edu/docs/nrpb0003